Abstract 1756P
Background
Gemcitabine + Docetaxel (G/D) is frequently used in the treatment of advanced/metastatic osteosarcoma (OS) and has been shown to induce autophagy, a proposed mechanism of chemoresistance. Hydroxychloroquine (HCQ) is a lysosome inhibitor that blocks chemotherapy-induced autophagy in multiple tumor types. We conducted a phase I/II clinical trial of G/D with HCQ to evaluate safety, tolerability, and preliminary efficacy in patients with advanced/metastatic OS.
Methods
Adolescent and adult patients (>/= 12 y.o.) with metastatic or advanced unresectable OS were enrolled in cohorts of 3 using a 3+3 dose escalation design to evaluate G/D with HCQ at 2 dose levels. Patients received G/D at standard doses of G=900mg/m2 IV d1 and d8 and D=75mg/m2 IV d8 every 21 days. HCQ was given at 600mg PO daily or 600mg PO BID until disease progression (PD), unacceptable toxicity, or consent withdrawal. Tumor response assessments occurred every 6 weeks. Additional patients were enrolled at the RP2D (G/D + HCQ 600mg PO BID) to estimate the event free survival at 4 months (4mo EFS), objective response rate (ORR), and overall survival. Archival tumor and on-treatment tumor biopsies were collected for autophagy biomarker analysis.
Results
31 OS patients aged 12-71 years were enrolled (Ph 1 n=13, Ph 2 n=25 all patients treated at RP2D). The 4mo EFS was 44% and 39% for all patients and those treated at RP2D, respectively. The median overall survival was 12.7 mo (all patients) and 9.5 mo (RP2D). Best response was 1 CR, 3 PR, 13 SD, and 11 PD by RECIST 1.1 (ORR = 13%). 7 patients had prolonged benefit with PR/SD > 9 mo. Study treatment was discontinued due to patient preference without PD (n=14), PD (n=15), death due to PD (n=1), or treatment delay (n=1). The most common grade 3/4 adverse events were hematologic toxicity (anemia n=15, neutropenia n=10, thrombocytopenia n=12), and nausea (n=10). 3 patients underwent resection of metastatic lesions on study after >4 months of G/D+HCQ and demonstrated pathologic complete response (CR).
Conclusions
The combination of G/D + HCQ is well tolerated in adolescents and adults with OS and demonstrated efficacy with prolonged SD and pathologic CRs observed. The contribution of HCQ to chemotherapy efficacy warrants further investigation.
Clinical trial identification
NCT03598595.
Editorial acknowledgement
Legal entity responsible for the study
J. A. Livingston.
Funding
Cures Within Reach.
Disclosure
J.A. Livingston: Financial Interests, Personal, Other, Nonprofit Strategic Advisory Board: Osteosarcoma Institute; Financial Interests, Institutional, Funding, Clinical trial funding and drug support: Genentech, Exelixis. All other authors have declared no conflicts of interest.
Resources from the same session
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06
1359P - Lack of Abscopal effect and radiotherapy-induced lymphocyte depletion in advanced non-small cell lung cancer (NSCLC) patients treated with atezolizumab and radiotherapy
Presenter: Alexander Meisel
Session: Poster session 06
1361P - The Stereotactic Radiosurgery-Brain Prognostic Index (SRS-BPI): A novel prognostic index for lung cancer patients with brain metastases eligible for SRS
Presenter: Andreas Koulouris
Session: Poster session 06